CapForce Inc.

CFOR

US68373L5057

Financial Technology (Fintech)

Delayed OTC Markets Other stock markets 09:37:27 2026-04-09 am EDT			5-day change	1st Jan Change
23.50 ^USD	+6.38%		-2.08%	+47.80%

Feb. 27	OpGen, Inc. has Changed its Name to CapForce Inc	CI
Jan. 15	OpGen, Inc. acquired iCapX Sdn. Bhd from AEI Capital Ltd. for $38.6 million.	CI

Top Premarket Gainers

Published on 09/29/2023 at 07:46 am EDT - Modified on 09/29/2023 at 07:47 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about CapForce Inc.

Feb. 27	OpGen, Inc. has Changed its Name to CapForce Inc	CI
Jan. 15	OpGen, Inc. acquired iCapX Sdn. Bhd from AEI Capital Ltd. for $38.6 million.	CI
Dec. 23	OpGen, Inc. Announces Resignation of David Lazar As President, Effective January 8, 2026	CI
Dec. 05	OpGen, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2025	CI
Dec. 05	CapForce International Holdings Ltd., Subsidiary of OpGen, Inc. Approves Promotion of Christian-Laurent Bonte as Chief Executive Officer, Effective December 1, 2025	CI
Nov. 19	OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	OpGen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-10-01	OpGen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-08-21	OpGen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-08-20	OpGen, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-07-22	OpGen, Inc. Announces Resignation of Christian-Laurent Benoit Bonte as Director, Effective July 17, 2025	CI
24-12-06	OpGen, Inc. Appoints Management Team	CI
24-11-15	OpGen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-21	OpGen, Inc. announced that it expects to receive $3 million in funding	CI
24-08-21	OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index	CI

OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero Lower Respiratory Tract Panels, Unyvero Urinary Tract Infection Panel, Unyvero System, and Unyvero Resources. The Unyvero LRT panels enable comprehensive detection of the most clinically relevant pathogens and antibiotic resistance markers. The Unyvero Urinary Tract Infection (UTI) panel simultaneously identifies a comprehensive range of pathogens and antibiotic resistance markers associated with urinary tract infections. The Unyvero system uses multiplex PCR technology to simultaneously test for a range of microorganisms and antibiotic resistance markers.

Employees

Sector

Financial Technology (Fintech)

More about the company